Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Combined modulation of polycomb and trithorax genes rejuvenates β cell replication
Josie X. Zhou, … , Seung K. Kim, Anil Bhushan
Josie X. Zhou, … , Seung K. Kim, Anil Bhushan
Published October 8, 2013
Citation Information: J Clin Invest. 2013;123(11):4849-4858. https://doi.org/10.1172/JCI69468.
View: Text | PDF
Research Article Metabolism

Combined modulation of polycomb and trithorax genes rejuvenates β cell replication

  • Text
  • PDF
Abstract

Inadequate functional β cell mass underlies both type 1 and type 2 diabetes. β Cell growth and regeneration also decrease with age through mechanisms that are not fully understood. Age-dependent loss of enhancer of zeste homolog 2 (EZH2) prevents adult β cell replication through derepression of the gene encoding cyclin-dependent kinase inhibitor 2a (INK4a). We investigated whether replenishing EZH2 could reverse the age-dependent increase of Ink4a transcription. We generated an inducible pancreatic β cell–specific Ezh2 transgenic mouse model and showed that transgene expression of Ezh2 was sufficient to increase β cell replication and regeneration in young adult mice. In mice older than 8 months, induction of Ezh2 was unable to repress Ink4a. Older mice had an enrichment of a trithorax group (TrxG) protein complex at the Ink4a locus. Knockdown of TrxG complex components, in conjunction with expression of Ezh2, resulted in Ink4a repression and increased replication of β cells in aged mice. These results indicate that combined modulation of polycomb group proteins, such as EZH2, along with TrxG proteins to repress Ink4a can rejuvenate the replication capacity of aged β cells. This study provides potential therapeutic targets for expansion of adult β cell mass.

Authors

Josie X. Zhou, Sangeeta Dhawan, Hualin Fu, Emily Snyder, Rita Bottino, Sharmistha Kundu, Seung K. Kim, Anil Bhushan

×

Figure 6

Knockdown of Mll1 combined with EZH2 expression results in increased proliferation of later passage MEFs.

Options: View larger image (or click on image) Download as PowerPoint
Knockdown of Mll1 combined with EZH2 expression results in increased pro...
(A) Passage 13 MEFs were transfected with scrambled siRNA (100 pM), pcDNA Myc-EZH2 (2 μg), Mll1 siRNA (100 pM), and both pcDNA Myc-EZH2 and Mll1 siRNA for 48 hours. BrdU was added in culture 48 hours before immunostaining for BrdU (red) and DAPI (blue) (original magnification, ×20). (B) Percentage of BrdU-positive MEFs in each experiment group. (C) Real-time qRT-PCR of Ink4a, Ezh2, and Mll1 mRNA in each group. n = 3 experiments. *P < 0.05, **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts